Initially, we examined whether treatment with the GREM1-neutralizing antibody could retard CRC hepatic metastasis and improve survival in comparison to an IgG isotype–treated control group (Supplementary Figure 20A). The gene discussed is GREM1; the disease is colorectal carcinoma.